Conicet plans to present a system to evaluate medical cannabis quality

Conicet authorities and members of the Cannabis Network will present the High-Level Technological Service, which allows evaluating the quality of the components of the preparations for medical purposes this Friday the 14th.

The latest CBD & Cannabis updates are now at your fingertips, with notifications and fresh information offered by our companion, the CBD News App. Stay up-to-date with marijuana stocks for investments, global market, cannabis legalization and more. CBD News is a mobile app that focuses exclusively on CBD. It brings you the very latest news in the CBD industry.

Presentation date and place

The presentation will take place this Friday, February, 14th at 1 p.m. at El Cruce Hospital in Florencio Varela, Buenos Aires. There, Conicet authorities and members of the Cannabis Network will present the High-Level Technological Service (STAN) of Cannabis Quality Control, which will allow for determining the quality of the components of the preparations made for medical purposes, the scientific institution informed. Conicet pointed out that “observational clinical methods will be implemented according to the patient’s diagnosis, to evaluate their efficacy and adverse effects, and, on the other hand, the botanical analysis of the cannabis used will be carried out.”

Participating in the launch of the new service will be Conicet President, Ana Franchi; members of the organization’s Cannabis Network; the Vice Minister of Health, and Vice President of UNAJ Arnaldo Medina; teachers from UNAJ; the director of the HEC Ariel Saez de Guinoa, along with specialists, researchers and NGO representatives.

Silvia Kochen, researcher and assistant professor of Neurology at the Faculty of Medicine of the University of Buenos Aires, will be responsible for the project on behalf of Conicet.

Kochen is in charge of the clinical trial to evaluate the effectiveness, safety, and tolerability of cannabis in adolescent and adult patients with refractory epilepsy at the Hospital ‘El Cruce’ whose approval through resolution 156/2019 was published six months ago in the Official Gazette.

Executing Unit of Studies in Neurosciences and Complex Systems in charge of the launch

According to the news agency Télam, in charge of the launch will be the Executing Unit of Studies in Neurosciences and Complex Systems (ENyS), dependent on Conicet, El Cruce Hospital and Universidad Nacional A. Jauretche (UNAJ).

Any individual, NGO, public, or private institution will be able to request this service from the ENyS as the activity will be aimed at “medical professionals, public health policy referents and managers, researchers, and all members of the community.”

Quality control of cannabis growers

“The idea is that Conicet will offer to do the quality control of the cannabis produced by cannabis growers. We have technical equipment and infrastructure to be able to control the components and guarantee their quality, above all because different end products can be obtained from the same plant,” a source at the agency explained to Télam.

The aim is that “any patient or cannabis grower can measure their product and they will also study the strains botanically. “The service is not about production but about production control,” the source added.

Self-cultivation prohibit

Three years after the law authorizing the use of medical cannabis was passed, users and families, such as Mama Cultiva, continue to be persecuted and criminalized because the law was not regulated and self-cultivation, even for medical purposes, is prohibited. This is provided for by law 27,350, which authorizes the use of medical cannabis in the Republic and prohibits self-cultivation.

__

(Featured image by Esteban Lopez via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in LA IZQUIERDA DIARIO, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.